ACTU
Actuate Therapeutics, Inc. Common stockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$49.79M
P/E Ratio
—
EPS
$-1.06
Beta
—
52W High
$11.99
52W Low
$2.05
50-Day MA
$3.55
200-Day MA
$6.08
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients facing serious diseases, with a particular focus on oncology. The company is advancing its proprietary drug candidates through rigorous clinical trials aimed at addressing significant unmet medical needs and enhancing patient outcomes. By concentrating on novel therapeutic mechanisms, Actuate is building a robust pipeline with the potential for strategic growth and investor value creation, positioning itself as a key player in the biotechnology landscape as it strives to make a meaningful impact.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -554.00% |
| Return on Assets | -120.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.34 |
| Price-to-Book | 7.48 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $23.71M |
| Float | $8.89M |
| % Insiders | 16.24% |
| % Institutions | 55.40% |
Analyst Ratings
Consensus ($17.78 target)
4
BuyData last updated: 4/7/2026